1	
2	
3	Title: Immune Markers Are Associated with Cognitive Performance in a Multiethnic
4	Cohort: the Northern Manhattan Study
5 6	Mitchell S. V. Elkind, MD, MS, ^{1,2} Michelle Moon, MS, ¹ Tatjana Rundek, MD, PhD, ³ Clinton B.
7	Wright, MD, MS, ⁴ Ken Cheung, PhD, ⁵ Ralph L. Sacco, MD, MS, ⁶ Mady Hornig, MD ²
8 9 10 11	¹ Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
12 13	² Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA
14 15 16	³ Department of Neurology, University of Miami, Miami, FL, USA
17 18	⁴ National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
19 20 21	⁵ Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA
22 23	⁶ Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA
24 25	Running title: Immune markers and cognition
26 27	Abstract word count: 249, Word Count: 4138 words
28 29 30	Key words: Cognition; Cohort Studies; Epidemiology; Immune Function; Innate immunity; Vascular dementia
31 32	Corresponding author:
33 34 35	Mitchell Elkind, MD, MS Columbia University Irving Medical Center 710 W. 168 th St
36 37 38	New York, New York, 10032 Tel: 212-305-1710, Fax: 212-305-1658 Email: mse13@columbia.edu
39 40	Twitter: @mitchElkind
41	Source of funding: NIH/NINDS R01 NS029993

- 43 Initially presented at American Academy of Neurology Annual Meeting May 2018.
- 44
- 45 Conflicts of Interest:
- 46 Dr. Elkind receives royalties from UpToDate for chapters on stroke and COVID-19.
- 47 Ms. Moon declares no conflicts of interest.
- 48 Dr. Cheung declares no conflicts of interest.
- 49 Dr. Sacco declares no conflict of interest.
- 50 Dr. Hornig declares no conflict of interest.
- 51 Dr. Rundek declares no conflict of interest.

53	Immune Markers Are Associated with Cognitive Performance in a Multiethnic Cohort: the
54	Northern Manhattan Study
55	OBJECTIVE: To determine whether immune protein panels add significant information to
56	correlates of cognition.
57	BACKGROUND: Immune mechanisms in vascular cognitive impairment and dementia are
58	incompletely characterized.
59	DESIGN/METHODS: A subsample of the prospective Northern Manhattan Study underwent
60	detailed neuropsychological testing. Cognitive scores were converted into Z-scores and
61	categorized into four domains (memory, language, processing speed, and executive function)
62	based on factor analysis. Blood samples were analyzed using a 60-plex immunoassay. We used
63	least absolute shrinkage and selection operator (LASSO) procedures to select markers and their
64	interactions independently associated with cognitive scores. Linear regression models assessed
65	cross-sectional associations of known correlates of cognition with cognitive scores, and assessed
66	model fit before and after addition of LASSO-selected immune markers.
67	RESULTS: Among 1179 participants (mean age 70±8.9 years, 60% women, 68% Hispanic),
68	inclusion of LASSO-selected immune markers improved model fit above age, education, and
69	other risk factors (p for likelihood ratio test<0.005 for all domains). C-C Motif Chemokine
70	Ligand 11 (CCL 11, eotaxin), C-X-C Motif Chemokine Ligand 9 (CXCL9), hepatocyte growth
71	factor (HGF), and serpin E1 (plasminogen activator inhibitor-1) were associated with each of the
72	domains and with overall cognitive function. Immune marker effects were comparable to
73	conventional risk factors: for executive function, each standard deviation (SD) increase in
74	CCL11 was associated with an effect equivalent to aging three years; for memory, HGF had
75	twice the effect of aging.
76	CONCLUSIONS: Immune markers associate with cognitive function in a multi-ethnic cohort.
77	Further work is needed to validate these findings and determine optimal treatment targets.
78 79	
80	

82	Non-standar	d Abbreviations and Acronyms
83		
84	95%CI	95% confidence interval
85	AD	Alzheimer Disease
86	CCL2	C-C Motif Chemokine Ligand 2
87	CCL3	C-C Motif Chemokine Ligand 3
88	CCL5	C-C Motif Chemokine Ligand 5
89	CCL11	C-C Motif Chemokine Ligand 11
90	CSF3	Colony stimulating factor 3
91	CRP	C-reactive protein
92	CXCL9	C-X-C Motif Chemokine Ligand 9
93	CXCL10	C-X-C Motif Chemokine Ligand 10
94	HGF	hepatocyte growth factor
95	IL12p40	interleukin-12 p40
96	IL1RA	interleukin-1 receptor antagonist
97	LASSO	Least Absolute Shrinkage and Selection Operator
98	LRT	likelihood ratio test
99	MCI	mild cognitive impairment
100	NOMAS	Northern Manhattan Study
101	SCF	stem cell factor
102	sFasL	soluble Fas ligand
103	TNFβ	tumor necrosis factor β
104	TRAIL	tumor necrosis factor-related apoptosis-inducing ligand
105		

106 Introduction

107 Communication between the brain and immune system is increasingly recognized as critical for brain health and neuroprotection after cerebrovascular, metabolic and microbial 108 challenges.^{1,2,3,4} Ouestions remain, however, regarding the role of inflammation in vascular and 109 110 neurodegenerative mechanisms of cognitive decline, mild cognitive impairment (MCI) and dementia; the specific inflammatory pathways that are most important;^{5,6} and the role of 111 112 inflammation in populations, particularly Hispanics, with a high burden of vascular risk factors but that have been underrepresented in research.^{7,8,9} Innate immunity, activation of complement 113 and microglia, and humoral and cellular immunity may all contribute.^{10,11,12,13} Much of this 114 115 work, moreover, is based on preclinical models or small sample sizes in humans. 116 We hypothesized that a multiplex immunoassay measuring 60 immune molecules would 117 provide insight into pathways involved in cognitive decline. We explored this hypothesis in a 118 population-based cohort study, the Northern Manhattan Study (NOMAS), a sample of Hispanic 119 and non-Hispanic participants from New York City.

120

121 METHODS

122 Study Population

NOMAS is a racially/ethnically diverse prospective cohort study consisting of 3,298 stroke-free participants enrolled between 1993 and 2001. The study was initially designed to evaluate effects of medical, socio-economic, and vascular risk factors on incidence of stroke and other vascular outcomes. Eligible participants were individuals residing in northern Manhattan for \geq 3 months in a household with a telephone, with no prior history of stroke, and age \geq 40 years old at the time of enrollment. Subjects were identified by random-digit dialing, and in-

person interview and assessment were conducted by trained bilingual research assistants. A
subcohort of 1290 participants included 1091 subjects remaining clinically stroke-free from the
original cohort as well as a sample of unrelated household members (n=199). MRI and detailed
neuropsychological assessments were conducted, and blood samples were collected; methods of
recruitment and characteristics of this sample have been described previously.¹⁴ The study was
approved by the Columbia University and University of Miami Institutional Review Boards, and
all participants provided informed consent.

136

137 Data collection

Demographics and risk factors were collected through in-person interviews, as described 138 previously.¹⁴ Race-ethnicity was determined by self-identification. Insurance status was defined 139 no insurance or Medicaid versus private insurance / Medicare²³. Educational achievement was 140 141 self-reported as number of years in school and degree achieved. Physical activity was evaluated by in-person questionnaire³⁵ and defined dichotomously. Smoking was categorized as current 142 143 (within the past year), former, or never smoker of cigarettes, cigars or pipes. Standardized questions adapted from the Behavioral Risk Factor Surveillance System assessed hypertension 144 145 and diabetes. Hypertension was defined either as participant self-report of hypertension, blood 146 pressure measurement of 140/90 mmHg or greater, or use of anti-hypertensive medication. 147 Diabetes was defined either as participant self-report of diabetes, fasting glucose of 126 mg/dL or greater, or use of insulin or oral anti-diabetic medications. 148

149

150 Cognitive assessment

151 Neuropsychological assessments were administered by trained bilingual research staff in English or Spanish, as previously described.¹⁵ We developed cognitive domain-specific scores to 152 enable interpretability of cognitive functions (Table e-1). Because of lack of population norms 153 for older cohorts, we used baseline neuropsychological scores as our cohort norms.¹⁶ To achieve 154 155 comparability, neuropsychological tests were standardized against cohort-specific normative 156 values. For timed tests (Color Trail 1, Color Trail 2 and Grooved Pegboard), because some 157 participants did not complete tasks within the maximum time allowed, we calculated their new 158 "imputed" time by adding penalty time to the maximum time allowed. The penalty time was obtained by multiplying the number of incomplete items by "expected time per correct items 159 160 completed" estimated using Kaplan-Meier methods. The standardized scores for individual tests 161 were then categorized into four key cognitive domains (memory, language, processing speed and 162 executive function) based on an exploratory factor analysis and prior findings.¹⁶ Thereafter, 163 cognitive domain-specific scores were calculated by taking the mean of the individual 164 standardized test scores selected for each domain. Cognitive outcomes were domain-specific z 165 scores (memory, language, processing speed and executive function) at baseline and a composite 166 cognitive function score obtained by averaging those four domain scores.

167

Multiplex immunoassay assessment

168 We completed assays of 60 immune molecules in 1179 participants from stored fasting plasma drawn at the time of a detailed cognitive assessment.^{17,18} We used a customized, highly 169 170 multiplexed, magnetic bead-based immunoassay.^{19,20} Our assay included molecules integral to 171 inflammatory responses, reflecting relative activation of Th1 (pro-inflammatory), Th2 (counter-172 regulatory, autoimmunity-promoting), Th17 (innate mucosal anti-pathogen defenses, including in gut), T regulatory, B (antibody-producing) and NK cells, and, more generally, innate and 173

adaptive (memory) arms of the immune system; chemoattractants (chemokines); growth factors
(including those vital to vascular remodeling); neurotrophic factors; cell adhesion markers; and
adipokines.

177 Plasma samples were coded, randomized and assayed in duplicate. Median fluorescence 178 intensities (MFI) of each analyte-specific immunoassay bead set were detected by the flow- and fluorescence-based Luminex 200TM detection platform (Luminex Corporation, Austin, TX).²¹ 179 180 Data were processed using a quality control (QC) algorithm that calibrates performance of an 181 expanded set of serial standard curves and an in-house plasma control run on every assay plate, monitoring intra- and inter-plate covariance (CV) and bead counts. Only plates with mean intra-182 183 assay %CV <15% were accepted. Samples failing to meet OC criteria were designated for re-run 184 when feasible (%CVs >25%, bead counts <30). MFI values exceeding machine limits of reliable 185 detection (>25,000) were excluded. Because interpolated concentrations can introduce bias for 186 samples with very low or high values in relation to the serial standard curves, averaged MFI values for all 60 cytokines were used in the final statistical analyses rather than absolute 187 concentrations.^{17,18} The final data set (test samples) had mean intra-assay %CV of 4.6% 188 189 (standard deviation [SD] 2.2%) and 0.5% of all possible intra-assay %CV values were >25%, 190 across all cytokines. Per-cytokine intra-assay %CV values ranged from 1.9% to 7.9%. 191

192 Statistical analyses

193 Distributions of socio-demographic characteristics and vascular risk factors for the study194 cohort were calculated.

Association between cognitive outcomes and immune markers was assessed using a two step hybrid Least Absolute Shrinkage and Selection Operator (LASSO) approach²²: first, we

197 performed the LASSO technique to select a subset among the 60 immune markers (logarithm 198 base 2-transformed and standardized) and all possible two-way interactions that linearly predicted each cognitive domain; variable selection was performed using 5-fold cross validation 199 200 based on the sum of squared error criterion. Then associations of selected markers with cognitive 201 function were assessed using linear regression models after adjusting for predictors of cognition 202 (i.e., age, sex, education, race-ethnicity, education, insurance status, diabetes, smoking status, 203 systolic blood pressure, diastolic blood pressure, high-density lipoprotein, low-density 204 lipoprotein, and estimated glomerular filtration rate). The independent association of the immune 205 marker ensemble was tested using likelihood ratio test (LRT) comparing two nested models: a 206 model that included the traditional predictors only (M1), and a model that included the LASSO-207 selected markers and interactions in addition to the traditional predictors (M2). R-squared (R^2) 208 was used to quantify the improvement of variance in the cognitive function explained by the 209 LASSO-selected immune marker ensemble. All analyses were performed using SAS version 9.4 210 (SAS Institute Inc. Cary, NC) and R version 3.4.

211

212 **RESULTS**

213 Description of cohort

There were 1179 participants with immune marker data available (Table 1). Mean age was 70±8.9 years and 60% were women. There was a high proportion of Hispanics (68%); mean education level was 10±5 years. There was a high burden of diabetes (28%) and other cardiovascular risk factors.

218

219 Associations of LASSO-selected immune markers with cognitive function

220	Inclusion of LASSO-selected immune markers collectively improved model fit over age
221	alone (p-value for LRT< 0.0001 for global score and for all domains) and over age,
222	demographics including education, and traditional risk factors for each cognitive outcome (p-
223	value <0.0001 for global score, memory, language, and executive function: $p = 0.0081$ for
224	processing speed; Table 2). For global cognitive function, the variance in cognition explained by
225	the immune markers was similar to that explained by age (model 0 and model 1-1), and the
226	addition of immune markers to a model that included age alone led to almost a doubling of the
227	R^2 (model 1-1 and model 1-2), implying that the effect of the immune markers was independent
228	and comparable in size to that of the effect of age. The effect of age alone was greatest for the
229	domain of processing speed ($R^2=0.17$) and least for language ($R^2=0.02$). The impact of adding
230	immune markers to age was greatest for executive function, for which R ² increased from 0.04 for
231	a model including only age to 0.17 when the immune markers were added.
232	Approximately 48% of the variance in global cognition was explained by a model

containing age, other demographics, and risk factors; the model fit improved by approximately
4.0% (from 48% to 50%) after inclusion of the immune markers.

235

236 Specific immune markers predicting cognitive functions

A subset of immune markers and their two-way interactions that predicted each cognitive function were selected using LASSO (Table e-2). C-C Motif Chemokine Ligand 11 (CCL11, or eotaxin), C-X-C Motif Chemokine Ligand 9 (CXCL9), hepatocyte growth factor (HGF) and serpin E1 (or plasminogen activator inhibitor-1) were consistently selected as being associated with overall cognitive function (Table 3) and with each of the neuropsychological domains (table e-3-6). In addition, sFasL, SCF, leptin, CCL3, CSF3 and CCL2 contributed to multiple cognitive

243	domains.	Interactions	between	CCL5	and serpir	E1,	between	CCL3	and	TNFβ	, between	CCL	.11
-----	----------	--------------	---------	------	------------	-----	---------	------	-----	------	-----------	-----	-----

- and IL1RA, between HGF and leptin, between TRAIL and IL12p40, between CCL11 and CCL5,
- and between CXCL10 and CXCL9 were also found in 2 or more domains.
- 246
- 247 Magnitude of immune marker effects
- 248 The magnitude of immune marker effects was comparable to that of conventional risk
- factors. For example, for executive function, each SD increase in CCL11 levels (β =-0.052,
- 250 p=0.016) was associated with an effect size equivalent to aging 3 years (3-year β =-0.048,
- 251 p<0.0001). HGF had twice the effect on memory function (β per SD=-0.06, p=0.012) as aging (β

252 per year =-0.03, p<0.0001).

253

254 Discussion

255 We found several immune molecules are cross-sectionally associated with cognitive 256 function in a predominantly Hispanic, but ethnically diverse, population. Many immune markers 257 were correlated, prompting us to use the LASSO technique to perform data reduction, thereby 258 extracting those molecules that were independently and most informatively associated with 259 cognition. As a group, those markers that were selected using LASSO had an explanatory impact 260 comparable and independent to that of age. After accounting for sociodemographic and vascular 261 risk factors, as well, the immune panel significantly improved model fit for the association with 262 cognition by approximately 4%.

These results suggest that serum immune markers have an independent association with cognition beyond that due to traditional risk factors for cognition and vascular disease. While the collective magnitude of these markers on cognition was modest, the magnitude of association for

several markers was comparable to that of other well-accepted risk markers of cognitive
impairment, including age. Cognitive decline is a complex, multifactorial phenomenon, and it is
unlikely that any single risk factor, immune pathway or marker accounts for a substantial
proportion of the variance in cognition. The total variance explained by models not including the
immune panel did not exceed 50%. Our results suggest that several immune pathways may be
involved and that approaches that affect multiple pathways simultaneously will be most likely to
have an impact, although further research is needed.

273 Individual markers most consistently associated with cognition were the chemokines CCL11 and CXCL9, the neurotrophic factor HGF, and serpin E1. Chemokines are a large family 274 275 of small protein molecules that play an important role in immune functions. CCL11 (eotaxin-1) 276 primarily binds to the CCR3 receptor and is important in eosinophil recruitment, allergic responses, and skewing toward a T helper (Th)-2 immune response. Its levels increase with age, 277 278 it can cross the blood brain barrier, and it has been postulated to promote aging-accelerated neurodegeneration.^{23,24,25} CCL11 impairs post-stroke recovery in animal models, although the 279 effect in humans appears to be reversed.²⁶ 280

CXCL9 is a member of the subfamily of CXC chemokines that lack a glutamic acid-281 282 leucine-arginine motif. They all share the CXCR3 receptor, and participate in Th1-type immune 283 responses, involving tissue infiltration by T cells as part of the innate immune response. CXCL9 284 is constitutively expressed on human brain-derived microvascular endothelial cells and astrocytes.²⁷ CXCL9 is upregulated by IFN- γ , induces activation of extracellular signal-regulated 285 kinases in cortical neurons in mice, and is involved in neuronal-glial interactions.²⁸ The CXC 286 chemokines increase with inflammation and infection of the CNS,²⁹ and are also up-regulated in 287 human brains with Alzheimer pathology.³⁰ 288

289 HGF is a neurotrophic factor with anti-apoptotic and angiogenesis effects that facilitates 290 dendritic arborization and has been associated with small artery disease among patients with cognitive impairment and AD.³¹ Consistent with our findings, these associations were 291 292 independent of other vascular risk factors, suggesting that the mechanisms by which HGF 293 contributes to cognitive impairment may be independent of traditional vascular risk factors. It is 294 increasingly evident that vascular and neurodegenerative contributions to cognitive aging and 295 dementia overlap, and that vascular mechanisms contribute to neurodegeneration. Immune 296 mechanisms that lead to small vessel disease may thus enhance the degenerative pathways that 297 lead to AD, either by impairing blood flow, enhancing inflammation, reducing regenerative 298 capacity, or inhibiting amyloid clearance.

299 Serpin E1 is the major inhibitor of the serine proteases tissue plasminogen activator and 300 urokinase, and thus acts as an inhibitor of fibrinolysis. Elevated levels potentially contribute to increased atherosclerosis, and risk of coronary artery events and stroke.³² In addition, serpin E1 301 302 inhibits activity of matrix metalloproteinases, which play a role in blood-brain barrier breakdown after ischemia.³³ Serpin E1 also plays a role in regulation of brain-derived neurotrophic factor 303 304 (BDNF), which must be converted from a pro-protein by plasmin. BDNF plays an important role in neuronal activity and memory.³⁴ A small study showed that serpin E1 is elevated in peripheral 305 blood with mild cognitive impairment;³⁵ however, our findings of higher levels of serpin E1 in 306 307 association with cognitive performance, and without interaction with BDNF, suggest that serpin 308 E1 production may exert a small protective effect.

Associations of immune markers with cognition were present for each of the individual
domains of cognitive function investigated, although several markers, as well as a global
cognitive measure, were present across all areas. Other markers selected by our data reduction

technique as contributing to two or more individual cognitive domains included sFasL (memory,
language function, processing speed, and global cognition), SCF (memory, processing speed, and
global cognition), CSF2 (memory and processing speed), leptin (language, executive function,
and global cognition), and the chemokines CCL2 (processing speed, executive function) and
CCL3 (language, executive function, and global cognition).

317 Evidence that levels of the chemokines CCL2, CCL3, CCL11 and CXCL9 are associated 318 with cognitive decline in our cohort support the hypothesis that the innate immune system contributes to cognitive impairment and dementia.^{36,37} Recent studies provide evidence that 319 320 increased amyloid-beta peptide activates the innate immune system via pattern recognition 321 receptors on microglia and astrocytes, contributing to hyperphosphorylation of *tau*. Sterile 322 inflammation can also be provoked by recognition of intracellular contents released from 323 necrotic cells through damage-associated molecular patterns. Elevations of these chemokines 324 could reflect chronic activation of innate immunity in brains of patients with cognitive impairment. There is also evidence that infections, such as herpes simplex virus-1, provoke 325 innate immunity, cause *tau* phosphorylation, and contribute to neurodegeneration.³⁸ Previous 326 327 studies in our cohort demonstrate that serologies against herpesviruses are associated with lower cognitive test scores.^{39,40} 328

Our results could have clinical implications since inflammation is potentially modifiable.
IL1β inhibition diminishes residual inflammatory risk for cardiovascular events,^{41,42} and some
antiviral agents are being tested for efficacy against AD, with variable results.^{43,44,45}
Acetylcholinesterase inhibitors also decreased IFNγ, TNFα, IL1β and IL6 secretion by immune
cells and enhanced innate resistance to viral infection *in vitro*.⁴⁶ Furthermore, the timing of

intervention also appears to be critical, underscoring the significance of long-term prospectiveinvestigations such as NOMAS.

Our study has limitations. First, measures of immune molecules and cognition were 336 337 obtained at a single time point, limiting our ability to make causal determinations. We continue 338 to follow our cohort over time, however, to provide longitudinal data. Second, immune markers 339 were not assessed in the cerebrospinal fluid or brain tissue, the site where injury occurs. 340 Nonetheless, blood biomarkers are increasingly recognized as indicators of neurodegenerative 341 activity and predictors of AD. Third, though our panel included 60 different immune-related markers, many others were not included. Fourth, we did not include MRI-derived biomarkers in 342 343 this study, nor did we have positron emission tomography to assess amyloid, *tau*, or microglial 344 activations. Our outcomes, however, were cognitive test scores, which may reflect multiple 345 pathologies and may ultimately have greater clinical relevance for patients. Our assay does not 346 provide a clinically useful panel of markers for the prediction of dementia currently. Our 347 findings require confirmation in other cohorts, and in longitudinal analyses, before they can be 348 used for clinical purposes.

Our study also has strengths. Our cohort represents a racially and ethnically diverse, elderly cohort at highest risk for cognitive decline and dementia. Many prior studies have not included large numbers of Black and Hispanic/Latino people. Our population was also wellcharacterized for demographic and medical risk factors. Our multiplex immune assay included a large number of molecules that may contribute to cognitive decline and dementia.

In conclusion, peripheral blood levels of several immune-related molecules, representing pathways related to innate immunity, neural repair, and thrombosis, may play a role in cognitive decline and dementia. As a group these factors modestly contribute to cognitive impairment,

- 357 independently of vascular risk factors associated with cognitive decline. These results speak to
- the ability of a multiplex immune assay to add information regarding pathways that may be
- involved in neurodegeneration in a diverse population. These findings also indicate the need for
- 360 further research on immune mechanisms in cognitive aging.

Table 1. Characteristics of the Cohort

		Overall
		N=1179
Age at visit 1, mean (±SD)	70 (±8.9)	
Men, n (%)		473 (40.1%)
Years of Education, mean	(±SD)	9.7 (±5.1)
Race-ethnicity, n (%)	Hispanic	785 (66.6%)
	Non-Hispanic Black	198 (16.8%)
	Non-Hispanic White	171 (14.5%)
Medical Insurance, n (%)	Medicaid or no Insurance	560 (47.5%)
	Medicare or Private Insurance	619 (52.5%)
Current Smokers, n (%)	182 (15.4%)	
Moderate or Heavy Physic	al Activity, n (%)	119 (10.2%)
Diabetes, n (%)		324 (27.5%)
Systolic blood pressure in	mm Hg, mean (±SD)	137 (±17.6)
Diastolic blood pressure in	mm Hg, mean (±SD)	78 (±9.6)
High-density lipoprotein, r	53.3 (±16.9)	
Low-density lipoprotein, n	115.6 (±35.1)	
eGFR, mean (±SD)	73.6 (±18.0)	
SD=standard deviation; eGI	FR=estimated glomerular filtratio	n rate

Table 2. Impact of immune markers and other factors on explanatory models for cognitive

- 373 test scores
- 374
- 375

	Adjusted R ² values for models containing the listed variables								
Cognitive function	Model 0 Model 1-1 Model 2-1 Model 1-2 Model 2-2								
	Immune markers* only	Age only	Age, demographics and risk factors**	Immune markers* and age	Immune markers*, age, demographics, and risk factors**				
Global Score	0.13	0.12	0.48	0.21^{+}	$0.50^{\text{\frac{4}{5}}}$				
Cognitive Domains									
Memory	0.12	0.11	0.31	0.18^{+}	0.33¥				
Language	0.09	0.02	0.39	0.10^{+}	$0.41^{\text{¥}}$				
Processing Speed	0.11	0.17	0.31	0.22*	0.32**				
Executive Function	0.14	0.04	0.39	0.17^{+}	0.42 [¥]				

376

* Immune markers refers to those immune markers and their interactions that were selected from
the Least Absolute Shrinkage and Selection Operator (LASSO) procedure as described in

379 Methods.

380 ** Demographics and risk factors: Sex, race-ethnicity, education, medical insurance type,

381 diabetes, smoking status, systolic blood pressure, diastolic blood pressure, high-density

382 lipoprotein, low-density lipoprotein, estimated glomerular filtration rate

* p<0.0001 for likelihood ratio test for effect of addition of immune markers selected by LASSO
 to model adjusted only for age (comparing Model 1-1 and Model 1-2)

p < 0.0001 for likelihood ratio test for effect of addition of immune markers selected by LASSO

to model adjusted for age, demographics and risk factors (comparing Model 2-1 and Model 2-2)

- 44 p=0.0081 for likelihood ratio test for effect of addition of immune markers selected by LASSO
- to model adjusted for age, demographics and risk factors (comparing Model 2-1 and Model 2-2)389
- 390
- 391
- 392
- 393
- 394
- 395 396
- 397
- 398
- 399

Immune marker [‡]	Estimate	Standard Error	р
CCL11	-0.036	0.017	0.033
HGF	-0.066	0.020	0.001
CXCL9	-0.029	0.017	0.092
SCF	-0.008	0.018	0.669
Leptin	0.027	0.019	0.160
sFasL	0.043	0.018	0.015
CCL3	0.024	0.019	0.193
Serpin_E1	0.037	0.016	0.022
Serpin_E1*CCL5	-0.021	0.014	0.123
HGF*Leptin	-0.036	0.017	0.031
CCL11*IL1RA	-0.008	0.012	0.485
CCL11*SCF	-0.033	0.015	0.025
sFasL*PDGFBB	-0.030	0.015	0.042
CCL5*CCL4	-0.001	0.020	0.962
CCL4*VCAM1	-0.029	0.022	0.186
CXCL10*IFNb	0.009	0.031	0.761
HGF*TRAIL	0.014	0.017	0.411
CXCL10*TGFa	0.011	0.035	0.745
CCL3*TNFb	0.007	0.014	0.599
TRAIL*IL12p40	0.025	0.019	0.179
CXCL10*IL5	-0.010	0.021	0.643
CCL3*LIF	-0.006	0.003	0.670
CCL11*sICAM1	0.020	0.017	0.243
CXCL10*VEGFD	0.013	0.016	0.432

402 Table 3: Association of immune markers and interactions with global cognitive score*

404

* Adjusted for age, sex, race-ethnicity, education, medical insurance type, diabetes, smoking
 status, systolic blood pressure, diastolic blood pressure, high-density lipoprotein, low-density
 lipoprotein, estimated glomerular filtration rate[†] Immune markers were log 2 transformed and
 standardized

409

410 CCL11 = C-C Motif Chemokine Ligand 11; CXCL9 = C-X-C Motif Chemokine Ligand 9;

411 HGF = hepatocyte growth factor; sFasL = soluble Fas ligand; SCF = stem cell factor;

412 CSF2 = Colony stimulating factor 2; CCL2 = C-C Motif Chemokine Ligand 2;

413 CCL3 = C-C Motif Chemokine Ligand 3; CCL4 = C-C Motif Chemokine 4;

414 IL12p40 = interleukin-12 p40; IL21 = interleukin 21; IL1a = interleukin 1a; CCL4 = C-C Motif

415 Chemokine Ligand 4; IFNb = interferon beta; PDGFBB = Platelet derived growth factor-BB;

416 TGFa = transforming growth factor α ; TRAIL = Tumor necrosis factor-related apoptosis-

417 inducing ligand

418

419

420

421

422

424 References

¹ Schwartz M, Peralta Ramos JM, Ben-Yehuda H. A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer's Disease. Journal of immunology (Baltimore, Md : 1950) 2020;204:243-50.

² Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol 2016;12:594-604.

³ Novellino F, Saccà V, Donato A, et al. Innate Immunity: A Common Denominator between Neurodegenerative and Neuropsychiatric Diseases. International journal of molecular sciences 2020;21.

⁴ Itzhaki RF, Golde TE, Heneka MT, Readhead B. Do infections have a role in the pathogenesis of Alzheimer disease? Nature reviews Neurology 2020;16:193-7.

⁵ Park JC, Han SH, Mook-Jung I. Peripheral inflammatory biomarkers in Alzheimer's disease: a brief review. BMB reports 2020;53:10-9.

⁶ Bostancıklıoğlu M. An update on the interactions between Alzheimer's disease, autophagy and inflammation. Gene 2019;705:157-66.

⁷ Forrester SN, Gallo JJ, Whitfield KE, Thorpe RJ. A Framework of Minority Stress: From Physiological Manifestations to Cognitive Outcomes. The Gerontologist 2019;59:1017-23.

⁸ Daulatzai MA. Role of stress, depression, and aging in cognitive decline and Alzheimer's disease. Current topics in behavioral neurosciences 2014;18:265-96.

⁹ Amariglio RE, Buckley RF, Rabin JS, et al. Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. Journal of Alzheimer's disease : JAD 2020;75:1437-46.

¹⁰ Rosenberg GA. Extracellular matrix inflammation in vascular cognitive impairment and dementia. Clinical science (London, England : 1979) 2017;131:425-37.

¹¹ Fu Y, Yan Y. Emerging Role of Immunity in Cerebral Small Vessel Disease. Front Immunol 2018;9:67.

¹² Noz MP, Ter Telgte A, Wiegertjes K, et al. Trained Immunity Characteristics Are Associated With Progressive Cerebral Small Vessel Disease. Stroke 2018;49:2910-7.

¹³ Poggesi A, Pasi M, Pescini F, Pantoni L, Inzitari D. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review. J Cereb Blood Flow Metab 2016;36:72-94.

¹⁴ Wright CB, Moon YP, Paik MC, Brown TR, Rabbani LR, Yoshita M, DeCarli C, Sacco RL, Elkind MSV. Inflammatory Biomarkers of Vascular Risk as Correlates of Leukoariosis. Stroke 2009;40:3466-71.

¹⁵ Wright CB, Gardener H, Dong C, Yoshita M, DeCarli C, Sacco RL, Stern Y, Elkind MS. Infectious Burden and Cognitive Decline in the Northern Manhattan Study. J Am Geriatr Soc. 2015 Aug;63(8):1540-5.

¹⁶ Siedlecki KL, Rundek T, Elkind MSV, Sacco RL, Stern Y, Wright CB. Using contextual analyses to examine the meaning of neuropsychological variables across samples of English-speaking and Spanish-speaking older adults. J Int Neuropsychol Soc 2011;12:1-11.

¹⁷ Breen EJ, Tan W, Khan A. The Statistical Value of Raw Fluorescence Signal in Luminex xMAP Based Multiplex Immunoassays. Sci Rep. 2016;6:26996.

¹⁸ Breen EJ, Polaskova V, Khan A. Bead-based multiplex immuno-assays for cytokines, chemokines, growth factors and other analytes: median fluorescence intensities versus their derived absolute concentration values for statistical analysis. Cytokine. 2015;71:188-98.

¹⁹ Hornig M, Montoya JG, Klimas NG, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv 2015;1:e1400121.

²⁰ Hornig M, Gottschalk G, Peterson DL, et al. Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome. Mol Psychiatry 2016;21:261-9.

²¹ Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000;243:243-55.

²² Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Ann Statist 2004;32(2):407-499.

²³ Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders. Front Psychiatry. 2018 Jun 14;9:241.

²⁴ Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477 (7362): 90–4.

²⁵ Arajuli B, Horiuchi H, Mizuno T, Takeuchi H, Suzumura A. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia 2015;63:2274–84.

²⁶ Roy-O'Reilly M, Ritzel RM, Conway SE, Staff I, Fortunato G, McCullough LD. CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke. Transl Stroke Res. 2017;8(6):578-584.

²⁷ Müller M, Carter S, Hofer MJ, Campbell IL. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10, and CXCL11 in neuroimmunity – a tale of conflict and conundrum. *Neuropathol Appl Neurobiol*. 2010;36(5):368–387.

²⁸ Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: In vitro ERK1/2 activation and role in Alzheimer's disease. *J Neuroimmunol*. 2000;108(1–2):227–235.

²⁹ Watson AES, Goodkey K, Footz T, Voronova A. Regulation of CNS precursor function by neuronal chemokines. Neurosci Lett. 2020;715:134533.

³⁰ Galimberti D, Schoonenboom N, Scarpini E, Scheltens P; Dutch-Italian Alzheimer Research Group. Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. *Ann Neurol.* 2003;53(4):547–548.

³¹ Zhu Y, Hilal S, Chai YL, et al. Serum Hepatocyte Growth Factor Is Associated with Small
Vessel Disease in Alzheimer's Dementia. *Front Aging Neurosci.* 2018;10:8. Published 2018 Jan
23. doi:10.3389/fnagi.2018.00008

³² Liu Y, Cheng J, Guo X, Mo J, Gao B, Zhou H, Wu Y, Li Z. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and meta-analysis involving 149,908 subjects. Gene. 2018 Oct 5;673:167-173. ³³ Keric N, Maier GS, Samadani U, Kallenberg K, Dechent P, Brueck W, Heuer J, Rohde V.
Tissue plasminogen activator induced delayed edema in experimental porcine intracranial
hemorrhage: reduction with plasminogen activator inhibitor-1 administration. Transl Stroke Res.
2012 Jul;3(Suppl 1):88-93.

³⁴ Angelucci F, Čechová K, Průša R, Hort J. Amyloid beta soluble forms and plasminogen activation system in Alzheimer's disease: Consequences on extracellular maturation of brainderived neurotrophic factor and therapeutic implications. CNS Neurosci Ther. 2019;25:303-313.

³⁵ Shen XN, Lu Y, Tan CTY, Liu LY, Yu JT, Feng L, Larbi A. Identification of inflammatory and vascular markers associated with mild cognitive impairment. Aging (Albany NY). 2019 Apr 30;11(8):2403-2419.

³⁶ Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015 Apr;14(4):388-405

³⁷ Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol. 2009;87(3):181-94.

³⁸ Wozniak MA, Frost AL, Itzhaki RF. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. *J Alzheimers Dis*. 2009;16(2):341-350.

³⁹ Katan M, Moon YP, Paik MC, Sacco RL, Wright CB, Elkind MS. Infectious burden and cognitive function: the Northern Manhattan Study. Neurology. 2013 Mar 26;80(13):1209-15.
doi: 10.1212/WNL.0b013e3182896e79. PMID: 23530151; PMCID: PMC3691781.

⁴⁰ Zhao C, Strobino K, Moon YP, Cheung YK, Sacco RL, Stern Y, Elkind MSV. *APOE* ε4
modifies the relationship between infectious burden and poor cognition. Neurol Genet. 2020 Jul
7;6(4):e462. doi: 10.1212/NXG.0000000000462. PMID: 32754642; PMCID: PMC7357411.

⁴¹ Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England journal of medicine 2017;377:1119-31.

⁴² Ridker PM. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Circulation research 2019;124:437-50.

⁴³ Ali MM, Ghouri RG, Ans AH, Akbar A, Toheed A. Recommendations for Anti-inflammatory Treatments in Alzheimer's Disease: A Comprehensive Review of the Literature. Cureus 2019;11:e4620.

⁴⁴ Tzeng NS, Chung CH, Lin FH, et al. Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2018;15:417-29.

⁴⁵ Dominy SS, Lynch C, Ermini F, et al. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Science advances 2019;5:eaau3333.

⁴⁶ Kokras N, Stamouli E, Sotiropoulos I, et al. Acetyl Cholinesterase Inhibitors and Cell-Derived Peripheral Inflammatory Cytokines in Early Stages of Alzheimer's Disease. Journal of clinical psychopharmacology 2018;38:138-43.